Unique challenges for commercializing in Canada

5 July 2018

Guy Payette, president of Innomar Strategies and a former director at Boehringer Ingelheim, has more than 30 years experience in navigating the Canadian healthcare system. In an Expert View piece, he gives his insight on how to bring a product to commercialisation in the Canadian market.

Commercializing a specialty pharmaceutical product in Canada is more complex than it originally appears. It requires proactive planning and unique considerations. Manufacturers new to Canada may be unfamiliar with the nuances of the Canadian healthcare system, and are not prepared for the length of review time and the approval process. If these specific considerations are not accounted for, manufacturers can experience delays in market access. In order to reach the market faster and drive product success, manufacturers should consider some of the following strategies when developing a commercialization plan.

Coordinating submissions and applications to expedite timelines

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK